The placement of a coronary stent restores blood flow in an obstructed artery, but the procedure does not eliminate all life risks. Death after stent placement remains a rare event, linked to specific mechanisms that cardiovascular research continues to document. Understanding these mechanisms helps identify the real danger factors, far from approximations.
Stent thrombosis: the most feared mechanism after angioplasty
Once deployed in the coronary artery, the stent is perceived by the body as a foreign object. Blood platelets can aggregate on its surface and form a clot capable of abruptly obstructing the vessel. This phenomenon, known as stent thrombosis, causes a myocardial infarction, which can be fatal.
Thrombosis can occur in the first hours following placement (acute thrombosis), within the first thirty days (subacute), or beyond a year (very late). Early thromboses are often linked to a technical defect during the procedure or poor expansion of the stent. Late thromboses, on the other hand, are more correlated with the premature cessation of antiplatelet therapy.
To delve deeper into this data, you can consult health analyses on Valbreon that detail the documented aggravating factors.
Dual antiplatelet therapy and risk of death: a delicate balance
After stent placement, a dual antiplatelet therapy combining aspirin and a second antiplatelet (clopidogrel, ticagrelor, or prasugrel) is prescribed. Its duration varies depending on the type of stent (bare or drug-eluting), the clinical context, and the patient’s associated conditions.
Too early de-escalation: a recent warning sign
The A-CLOSE trial, presented in a “Hot Line” session at the ESC 2026 congress and published in the New England Journal of Medicine, studied over 3,200 patients at high ischemic risk. The results show that switching too early to a single antiplatelet increases all-cause mortality. The mortality rate with clopidogrel alone reached 1.3%, compared to 0.4% with prolonged dual therapy beyond twelve months.
Conversely, prolonged dual therapy exposes patients to more major bleeding events (4.1% versus 1.8% with monotherapy). The decision to extend or shorten treatment therefore relies on a balance between ischemic risk and bleeding risk, specific to each patient.
When stopping treatment becomes critical
A clinical case documented by prevention-medicale.org illustrates this danger: a 67-year-old man, a stent carrier and on antiplatelet therapy, had his treatment interrupted before a non-urgent surgical procedure. Death occurred three days after the cessation, due to coronary thrombosis. The investigation highlighted a communication failure between the anesthesiologist and the surgeon.
Any interruption of antiplatelet therapy, even temporary, requires strict coordination between the cardiologist and the surgical team. Isolated cessation without cardiological advice is a major risk factor for death.
Late post-stent bleeding: an underestimated danger
The medical debate often focuses on thrombosis, but recent data reveal another mortality factor: bleeding complications occurring after hospital discharge.
A registry analysis of patients who underwent angioplasty with stent shows that late bleeding, beyond six months, is more strongly associated with mortality than late ischemic complications. Digestive, cerebral, or surgical bleeding events while on antiplatelet therapy represent a significant portion of these occurrences.
This data changes the understanding of post-stent risk. Follow-up should not be limited to monitoring for restenosis or thrombosis. Regular assessment of bleeding risk, considering age, renal function, and associated treatments, is an integral part of death prevention.
Risk factors for death after stent placement: patient profile and clinical context
Not all patients present the same level of risk after coronary angioplasty. Several elements directly influence the likelihood of serious complications:
- Diffuse coronary artery disease, affecting multiple arteries, increases the risk of ischemic events even after successful revascularization.
- Diabetes, chronic kidney failure, and advanced age both worsen the risk of thrombosis and the bleeding risk under antiplatelet therapy.
- A history of poor medication adherence is a predictive factor for stent thrombosis, as even a brief interruption of treatment can trigger a clot.
- The type of stent implanted plays a role: drug-eluting stents, coated with an antiproliferative drug, reduce the risk of restenosis but require a longer duration of dual therapy than bare stents.
Regular cardiological follow-up, with reevaluation of treatment at each consultation, remains the main lever to adapt the therapeutic strategy to the evolving profile of the patient.
Post-stent follow-up and death prevention: what recent research changes
The data from the A-CLOSE trial and registries on late bleeding modify clinical practice in two ways. The first concerns the duration of treatment: in patients at high ischemic risk, extending dual therapy beyond one year reduces mortality, provided that the bleeding risk is acceptable. The second pertains to perioperative management: any scheduled surgery in a stent carrier requires a protocol for bridging validated by the cardiologist.
The patient with a stent must systematically inform any healthcare professional of their antiplatelet therapy, including dentists or general practitioners prescribing anti-inflammatories. Any unusual bleeding (gums, urine, black stools) warrants prompt consultation.
The risk of death after stent placement is not limited to the procedure itself. It extends into the months and years that follow, driven by the fragile balance between protection against thrombosis and exposure to bleeding. Research from 2026 confirms that this regularly reevaluated balance remains the most determining factor for long-term survival.
